CHRISTOPHER KING (CWRU, USA)
LUCIO LUZZATTO (MUHIMBILI U, TANZANIA)
NICHOLAS WHITE (OXFORD/MAHIDOL, THAILAND)
SEBASTIAN MIKOLAJCZAK (CIDR, USA)
André Siqueira: is an Infectious Diseases Physician and Public Health Researcher working in the Acute Febrile Illness Clinical Research Group at Fiocruz. His main research contributions are related to the studies of the epidemiology and treatment of malaria in Brazil, especially P. vivax. By describing and analyzing characteristics of the dynamics of malaria Dr Siqueira is particularly interested in developing and evaluating strategies to improve antimalaria efficacy assessments in P. vivax and on how to accelerate and sustain elimination of transmission in changing epidemiology scenarios. One of the aspects he has recently started working comprises the study of non-malarial causes of fever and how to improve the integration in both case-management and disease surveillance leading to more efficient health strategies.
Institutional affiliation: Instituto Nacional de Infectologia Evandro Chagas, Fiocruz, Brazil
is an Associate Professor at the Nuffield Department of Medicine (NDM) in the University of Oxford. He is a Principal Investigator at the Jenner Institute and a Wellcome Trust Fellow. Arturo is currently leading a group working on a research program to develop vaccines for 5 neglected and emerging infectious diseases, including two in pre-clinical phase: Chagas disease and Dengue; and three that have entered clinical stage: P. vivax malaria, Zika and Chikungunya.
His work is supported by the Wellcome Trust, the MRC, Department of Health through InnovateUK, the Brazilian and Mexican government. Recently, he has contributed to the establishment of strong links between Oxford and Mexico supported by formal agreements between the NDM and six leading universities and public health laboratories and has extended his program for vaccine development to studies in Mexico. This has led to the creation of the NDM-Mexico initiative to support collaborative work between various research groups in Oxford with scientists from Mexico, as well as student and academic exchanges.
Institutional affiliation: (University of Oxford, United Kingdom)
Brice Campo: Director Drug Discovery at Medicines for Malaria Venture (MMV). He leads drug discovery activities in the context of individual projects and pharmacology platforms. As Director Drug Discovery, Brice provides scientific advice and leadership to portfolio of drug discovery activities projects and pharmacology platforms. He works with partners from both academia and industry in order to deliver pertinent and optimal biological test cascades as well as safe and efficacious pre-clinical candidate which will be part of the next generation of anti-malarials. Brice has a particular interest in molecules and biological assays that tackle the liver stage of the parasite and more precisely the hypnozoites reservoir in order to find the new drugs that will help eradicate Malaria. He joined MMV in November 2011, bringing with him more than 13 years of experience in drug discovery, gained primarily with the Genomic Institute of the Novartis Foundation (GNF) and Addex Pharmaceuticals S.A. He has broad experience in molecular pharmacology and drug discovery in several disease areas such as Neuroscience, Metabolic Disease and Inflammation, and has successfully led and contributed to teams at all stages of drug discovery. Brice holds a PhD in Neuroscience and Immunology from the University of Sheffield (UK) and has published a significant number of scientific papers and patent applications.
Institutional affiliation: Medicines for Malaria Venture, Switzerland
Dennis Kyle: is a Distinguished University Health Professor in the Department of Global Health, College of Public Health at the University of South Florida. He completed a PhD at Clemson University and a postdoctoral position at the University of Georgia before he began a 21-year association with the Walter Reed Army Institute of Research. During this time he led key efforts with the US Army’s Drug Development Program, eventually serving as Deputy Director of the Division of Experimental Therapeutics.
Dr. Kyle research interests include the discovery and development of new antiparasitic drugs and elucidation of mechanisms of antimalarial drug resistance. Recently he has led multidisciplinary efforts to develop high-throughput platforms for discovery of anti-hypnozoite drugs and has characterized novel phenotypes of artemisinin-resistance in P. falciparum malaria that include altered cell cycle regulation of asexual erythrocytic stages.
Institutional affiliation: (University of Georgia, USA)
Elizabeth Winzeler: is a Professor at the University of California, San Diego, School of Medicine. She leads a group that uses systematic, data intensive methods to solve problems at the interface of host pathogen biology typically involving large collections of chemical screening data and whole genome sequencing at UC San Diego. She is a fellow of the American Academy in Microbiology. She has received awards from the Keck Foundation, the Ellison Medical Foundation, and the Bill and Melinda Gates Foundation. In 2014 she was awarded the Bailey-Ashford Medal for distinguished achievements in tropical medicine.
Institutional affiliation: (University of California, USA)
Iveth J. González: Medical doctor from Colombia with a PhD degree in basic sciences from the University of Lausanne in Switzerland. She has worked on basic and clinical research applied to tropical diseases, more specifically malaria, leishmaniasis and Chagas disease. She has more than 15-year experience on malaria research and is currently the head of the Malaria programme at FIND (Foundation for Innovative New Diagnostics) in Geneva, where she has contributed to the development, implementation and quality assurance of diagnostic solutions for malaria control and elimination.
Institutional affiliation: Head of Malaria Foundation for Innovative New Diagnostics, Switzerland
Dr. Vinetz is a Fellow of the Infectious Diseases Society of America, the American Society of Tropical Medicine and Hygiene, the American College of Physicians and member of the American Society for Clinical Investigation and the Association of American Physicians.
The overall theme of Dr. Vinetz research program in tropical infectious diseases is to bring fundamental laboratory-based research to the field, and, vice-versa, to learn fundamental aspects of infectious disease pathogenesis from patients in the field setting. His laboratory currently focuses on two diseases: malaria and leptospirosis, with both laboratory- and field-based activities. He carries out NIH-funded research activities in Peru.
Institutional affiliation: (UC San Diego, School of Medicine, CA)
Kevin Baird: earned a B.Sc. in Microbiology, M.Sc. in Biochemistry, and Ph.D. in Medical Zoology. He served 22 years on active duty in the US Navy Medical Service Corps as a Microbiologist specializing in research on malaria prevention, control, treatment, epidemiology, and immunology. He has long focused on Plasmodium vivax malaria, in particular on the problem of G6PD deficiency and primaquine therapy against relapse of that species. The unit in Jakarta undertakes clinical trials of therapies against relapse of P. vivax, principally in Indonesian soldiers but also in village settings, in addition to laboratory and field studies of G6PD deficiency biochemistry, diagnostics, and epidemiology.
Institutional affiliation: (University of Oxford, United Kingdom)
Kevin Kobylinski: My research interests are heavily rooted in medical entomology and focused on developing and characterizing novel vector control interventions. My primary research interest for the last several years has been characterizing the utility of ivermectin mass drug administration (MDA) for malaria parasite transmission suppression. Ivermectin is a broad spectrum anthelminthic used to treat and eliminate numerous neglected tropical diseases in humans. Ivermectin is an extremely safe drug used in onchocerciasis and lymphatic filariasis elimination campaigns and given to more than 300 million people annually. Ivermectin at human and animal relevant concentrations has been shown to kill all Anopheles vectors tested to date, covering most of the primary malaria vectors across the globe. In addition to the direct killing effect, ivermectin has sublethal effects including inhibition of re-feeding, inhibition of sporogony, and reduction in fecundity. Recent in vitro and in vivo evidence suggests that ivermectin may also inhibit liver stage Plasmodium development. Field studies in West Africa demonstrate that ivermectin MDAs can reduce longevity of wild Anopheles and reduce P. falciparum transmission burden. Clinical trials are underway to assess the safety and efficacy of ivermectin with various artemisinin combination therapies for possible use in MDAs. Field studies of ivermectin MDA are being initiated in Southeast Asia to assess capabilities to suppress P. vivax and P. falciparum transmission.
Institutional affiliation: (AFRIMS), Thailand
Mark Styczynski: earned a B.Sc. in Microbiology, M.Sc. in Biochemistry, and Ph.D. in Medical Zoology. He served 22 years on active duty in the US Navy Medical Service Corps as a Microbiologist specializing in research on malaria prevention, control, treatment, epidemiology, and immunology. He has long focused on Plasmodium vivax malaria, in particular on the problem of G6PD deficiency and primaquine therapy against relapse of that species. The unit in Jakarta undertakes clinical trials of therapies against relapse of P. vivax, principally in Indonesian soldiers but also in village settings, in addition to laboratory and field studies of G6PD deficiency biochemistry, diagnostics, and epidemiology.
Institutional affiliation: (University of Oxford, United Kingdom)
Michael White: is an MRC Research Fellow in Imperial College London and Visiting Scientist in The Walter and Eliza Hall Institute, Melbourne working on the development of mathematical models of Plasmodium vivax transmission, and the application of serological models to data on naturally-acquired and vaccine-induced antibody responses. In 2017, Dr White will join Prof Ivo Mueller's lab in Institut Pasteur, Paris where he will continue to work on P. vivax.
Institutional affiliation: Imperial College, Uk
Nick White: Professor White’s diverse interests include the epidemiology, pathophysiology and management of uncomplicated and severe malaria, meliodosis, enteric fever, tetanus, dengue haemorrhagic fever, Japanese encephalitis and tuberculosis. His interests at present include the pathophysiology and treatment of severe malaria, the prevention of antimalarial drug resistance using artemisinin-based combinations. and the biology of relapse in vivax malaria.
Institutional affiliation: (Mahidol Oxford Tropical Medicine Research Unit, Thailand)
lobal Malaria Programme is responsible for the coordination of WHO's global efforts to control and eliminate malaria
and sets evidence-based norms, standards, policies and guidelines to support malaria-affected countries around the world.
A national of Spain, Dr Alonso has spent over 30 years in public health. His scientific research work has focused on key determinants of morbidity and mortality in the most vulnerable population groups. He has published over 300 articles in international peer-reviewed journals – primarily on malaria treatment, vaccine trials and preventive therapies – and has served on several national and international committees. He is particularly committed to capacity building of both institutions and individuals, primarily in Africa
Prior to taking up the WHO position, Dr Alonso was Director of the Barcelona Institute for Global Health (ISGlobal) and Professor of Global Health at the University of Barcelona, and President of the Governing Board of the Manhiça Foundation and the Manhiça Health Research Centre in Mozambique.
Institutional affiliation: World Health Organization, Switzerland
PhD is a Professor in the Center for Global Health & Diseases, at Case Western Reserve University, in Cleveland, Ohio. His prior research experience included a postdoctoral fellowship in the Laboratory of Parasitic Diseases of the US National Institutes of Health and he received his PhD degree from CWRU. He has conducted population-based research on many aspects of malaria in Papua New Guinea and Madagascar. His work focused on Plasmodium vivax, has concentrated on human and parasite genetic variation and susceptibility to infection and pathogenesis. Findings that Duffy-negative people are susceptible to P. vivax infection and disease in Madagascar have prompted new studies on this parasite’s interaction with the red blood cell. Pursuing insights into P. vivax invasion of Duffy- positive and Duffy-negative red blood cells has also required new strategies for in vitro culture.
Institutional affiliation: (Case Western Reserve University, USA)
is a preeminence faculty scholar with decades of experience studying malaria and other vector-borne diseases. He arrives at the University of Florida from Johns Hopkins, where he was a faculty member in the W. Harry Feinstone Department of Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public health. Currently, he is the director of the CDC Southeastern Regional Center of Excellence in Vector Borne Diseases.
Much of Dr. Dinglasan’s research has focused on finding a vaccine that will prevent malaria transmission. As part of this effort, Dinglasan has focused specifically on ways in which interactions between the human malaria parasites Plasmodium falciparum and P. vivax and the Anopheles mosquito midgut can be better understood to disrupt the transmission of these pathogens to humans. To better study these interactions, he is interested in the application of mass spectrometry toward the molecular and cellular analysis of critical transition steps during malaria parasite transmission. He has also studied how nanoparticle technology can contribute to the development of vaccine and drug delivery systems.
His interest in preventing the spread of malaria has led him to study the developmental biology of the malaria parasite – concentrating on the parasite’s sexual stage. This stage of the parasite’s life cycle does not actually cause disease in humans, so it has not been studied as thoroughly as the erythrocytic stages, where the parasite infects red blood cells and causes disease.
Institutional affiliation: (University of Florida, USA)
Ingrid Felger: is head of the Molecular Diagnostics unit at Swiss Tropical & Public Health Institute, Basel, Switzerland. Since 1996 she has been leading the development of new tests for individual diagnosis and population studies. Since her post-doctoral work at the Papua New Guinea Institute of Medical Research Dr Felger has undertaken major research projects on molecular epidemiology of Plasmodium vivax and P. falciparum. She has developed molecular parameters to describe parasite infection and transmission dynamics and survival of individual parasite clones in the host. Currently Dr Felger conducts molecular-epidemiological research on malaria, HIV and Leishmaniasis within international collaborations in Europe, Africa, Asia, Oceania, and Brazil.
Institutional affiliation: University of Basel, Switzerland
Ric Price: is Professor of Global Health at the Menzies School of Health Research (Darwin, Australia) and Professor of Tropical Medicine at the Centre of Tropical Medicine (University of Oxford, UK). His research focuses on improving the diagnosis and management of malaria. He is head of the clinical module of the WorldWide Antimalarial Resistance Network (WWARN) and co-Chairs the Vivax Working Group of the Asia Pacific Malaria Elimination Network (APMEN).
Institutional affiliation: Menzies School of Health Research, Australia/University of Oxford, UK
Scott Miller: is a board-certified internist and infectious diseases specialist, who serves as Deputy Director of the Malaria team that guides the Bill & Melinda Gates Foundation’s research and development strategy and efforts to eradicate malaria.
A graduate of Dartmouth College (BA, Biology) and Columbia University College of Physicians & Surgeons, he joined the Foundation in 2015 after a 26 year career in the U.S. Army Medical Department. After seven years as a practicing internist, he spent the remainder in the federal research laboratories on malaria product development, international clinical trials, research ethics and management of R&D programs. This included 6 years stationed in Bangkok, Thailand conducting clinical trials in the Greater Mekong region, and leading clinical drug trials in East Africa and Gabon. He has been part of the Army’s leadership team for the development of malaria rapid diagnostics, intravenous artesunate for severe malaria, tafenoquine for vivax malaria treatment, new agents for malaria chemoprophylaxis, as well as leading Department of Defense efforts to evaluate new treatment interventions for persistent post-concussion symptoms and Ebola virus disease.
Dr. Miller holds a dual academic appointment in Medicine and Preventive Medicine at the military’s medical school, Uniformed Services University of the Health Sciences in Bethesda, Maryland. He has authored 70 peer-review publications and book chapters, and has served as consultant on several R&D programs and safety monitoring boards. He is a Fellow of the American College of Physicians and the Infectious Diseases Society of America, and holds a Certification in Tropical Medicine and Travelers’ Health from ASTMH.
Institutional affiliation: Bill & Melinda Gates Foundation’s
is a group leader at the Walter and Eliza Hall Institute, Australia. Her research focuses on the discovery of new host-pathogen interactions that govern successful malaria infection. She studies P. falciparum and P. vivax parasite adhesins that are required for entry into red blood cells as well as merozoite surface proteins that bind to human complement proteins. Her lab combines molecular, cellular and structural biology methods to study the mechanisms of parasite invasion and complement evasion strategies of malaria parasites. The overarching aim is to rationally design and generate new inhibitors or antibodies that are able to block these interactions and hence, stop the recurrent infection in the host.
Institutional affiliation: (Walter and Eliza Hall Institute of Medical Research, Australia)